...
首页> 外文期刊>Evidence-based nursing >Review: lifestyle or pharmacological interventions prevent or delay type 2 diabetes in people with impaired glucose tolerance.
【24h】

Review: lifestyle or pharmacological interventions prevent or delay type 2 diabetes in people with impaired glucose tolerance.

机译:综述:生活方式或药物干预措施可预防或延缓糖耐量异常人群的2型糖尿病。

获取原文
获取原文并翻译 | 示例
           

摘要

Meta-analysis using a random effects model showed that both lifestyle interventions (diet, exercise, or both) and pharmacological interventions (oral diabetes drugs [acarbose, flumamine, glipizide, metformin, or phenformin] or an anti-obesity drug [orlistat]) reduced the incidence of type 2 diabetes (table); 2 trials assessing troglitazone were excluded from the meta-analysis because the drug had been removed from several markets worldwide because of liver toxicity. In 1 trial, jiangtang bushen (a Chinese herbal) did not reduce diabetes (table). Adverse events related to pharmacological interventions (gastrointestinal and hypoglycaemic symptoms) were more common in the treatment groups (no statistical tests reported).
机译:使用随机效应模型的荟萃分析显示,生活方式干预(饮食,运动或两者兼有)和药理干预(口服糖尿病药物[阿卡波糖,氟胺,格列吡嗪,二甲双胍或苯甲双胍]或抗肥胖药[orlistat])减少2型糖尿病的发生率(表);荟萃分析未包括2项评估曲格列酮的试验,因为该药物由于肝毒性已从全球多个市场中撤出。在一项试验中,降糖补肾(中草药)未降低糖尿病(表)。在治疗组中,与药理学干预有关的不良事件(胃肠道和低血糖症状)更为常见(无统计试验报道)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号